CDER Seeks To Limit Evidence On Future Avastin Studies At June Hearing

FDA's Center for Drug Evaluation and Research says its discussions with Genentech about a proposed confirmatory trial in metastatic breast cancer are irrelevant to the withdrawal of bevacizumab's accelerated approval for the indication.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet